- cafead   Jun 18, 2024 at 12:02: PM
via Bucking its recent winning streak in oncology, AstraZeneca reported Tuesday that its AKT inhibitor Truqap failed to significantly boost overall survival in patients with triple-negative breast cancer.
article source
article source